Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Harvey S. Marver is active.

Publication


Featured researches published by Harvey S. Marver.


The New England Journal of Medicine | 1972

Intermittent Acute Porphyria — Demonstration of a Genetic Defect in Porphobilinogen Metabolism

Urs A. Meyer; L. James Strand; Manfred Doss; A. Clegg Rees; Harvey S. Marver

Abstract In a family with intermittent acute porphyria (IAP) five affected members were found to have decreased erythrocyte uroporphyrinogen I (URO)-synthetase activity, when compared to unaffected...


Journal of Clinical Investigation | 1972

Decreased Red Cell Uroporphyrinogen I Synthetase Activity in Intermittent Acute Porphyria

L. James Strand; Urs A. Meyer; Bertram F. Felsher; Allan G. Redeker; Harvey S. Marver

Intermittent acute porphyria has recently been distinguished biochemically from other genetic hepatic porphyrias by the observation of diminished hepatic uroporphyrinogen I synthetase activity and increased delta-aminolevulinic acid synthetase activity. Since deficient uroporphyrinogen I synthetase may be reflected in nonhepatic tissues, we have assayed this enzyme in red cell hemolysates from nonporphyric subjects and from patients with genetic hepatic porphyria. Only patients with intermittent acute porphyria had decreased erythrocyte uroporphyrinogen I synthetase activity which was approximately 50% of normal. The apparent K(m) of partially purified uroporphyrinogen I synthetase was 6 x 10(-6)m in both nonporphyrics and patients with intermittent acute porphyria. These data provide further evidence for a primary mutation affecting uroporphyrinogen I synthetase in intermittent acute porphyria. Further-more, results of assay of red cell uroporphyrinogen I synthetase activity in a large family with intermittent acute porphyria suggest that this test may be a reliable indicator of the heterozygous state.


Journal of Clinical Investigation | 1971

Inducible heme oxygenase in the kidney: a model for the homeostatic control of hemoglobin catabolism

Neville R. Pimstone; Peter Engel; Raimo Tenhunen; Paul T. Seitz; Harvey S. Marver; Rudi Schmid

We have recently identified and characterized NADPH-dependent microsomal heme oxygenase as the major enzymatic mechanism for the conversion of hemoglobin-heme to bilirubin-IXalpha in vivo. Enzyme activity is highest in tissues normally involved in red cell breakdown, that is, spleen, liver, and bone marrow, but it usually is negligible in the kidney. However, renal heme oxygenase activity may be transiently increased 30- to 100-fold following hemoglobinemia that exceeded the plasma haptoglobin-binding capacity and consequently resulted in hemoglobinuria. Maximal stimulation of enzyme activity in rats is reached 6-16 hr following a single intravenous injection of 30 mg of hemoglobin per 100 g body weight; activity returns to basal levels after about 48 hr. At peak level, total enzyme activity in the kidneys exceeds that of the spleen or liver. Cyclohexamide, puromycin, or actinomycin D, given just before, or within a few hours after, a single intravenous injection of hemoglobin minimizes or prevents the rise in renal enzyme activity; this suggests that the increase in enzyme activity is dependent on continued synthesis of ribonucleic acid and protein. The apparent biological half-life of renal heme oxygenase is about 6 hr. These observations indicate that functional adaptation of renal heme oxygenase activity reflects enzyme induction either directly or indirectly by the substrate, hemoglobin. Filtered rather than plasma hemoglobin appears to regulate renal heme oxygenase activity. Thus, stabilization of plasma hemoglobin in its tetrameric form with bis (N-maleimidomethyl) ether, which diminishes its glomerular filtration and retards it plasma clearance, results in reduced enzyme stimulation in the kidney, but enhances its activity in the liver. These findings suggest that the enzyme is localized in the tubular epithelial cells rather than in the glomeruli and is activated by luminal hemoglobin. Direct support for this concept was obtained by the demonstration of heme oxygenase activity in renal tubules isolated from rabbits that had been injected with hemoglobin.


Journal of Clinical Investigation | 1971

Erythropoietic protoporphyria: evidence for multiple sites of excess protoporphyrin formation

Perry L. Scholnick; Harvey S. Marver; Rudi Schmid

A patient with erythropoietic protoporphyria was studied to determine the sites of excess protoporphyrin formation. The patients protoporphyrin was pulse labeled by the simultaneous administration of the precursors 2-glycine-(14)C and 3,5-delta-aminolevulinic acid-(3)H; delta-aminolevulinic acid preferentially labels the hepatic pool. Blood and feces were studied at intervals for the next 14 days. Protoporphyrin was extracted from erythrocytes, plasma, and feces, identified by thin-layer chromatography, and quantitated spectrophotometrically, and its specific activity was determined by liquid scintillation spectrometry. Analysis of the kinetic and isotopic data indicated at least two sources of protoporphyrin, one localized in the erythroid cells, a second in the liver. The liver was responsible for the majority of the excess protoporphyrin. This report thus provides evidence of a genetic porphyria exhibiting an abnormality of porphyrin biosynthesis in at least two tissues. We propose that the disease, erythropoietic protoporphyria, be renamed erythrohepatic protoporphyria.


The American Journal of Medicine | 1966

Acute intermittent porphyria: New morphologic and biochemical findings

Mark G. Perlroth; Donald P. Tschudy; Harvey S. Marver; Costan W. Berard; Robert F. Zeigel; Miloslav Rechcigl; Annie Collins

Abstract This paper presents the results of postmortem morphologic and biochemical studies on a patient with acute intermittent porphyria (AIP); there was evidence suggesting the syndrome of inappropriate antidiuretic hormone (ADH) release. Examination of the brain revealed injury to the median eminence and bilateral loss of neurones of the supraoptic and paraventricular nuclei. This represents the first correlation of a specific hypothalamic lesion with the syndrome of inappropriate ADH release. The activity of hepatic δ-aminolevulinic acid synthetase (ALA synthetase), a mitochondrial enzyme which normally is rate-limiting for porphyrin biosynthesis, was increased sevenfold above normal. The high level of this enzyme explains the increased porphyrin precursor excretions seen in AIP. Three general mechanisms, including an operator constitutive mutation, have been discussed as possible explanations of the induction of hepatic ALA synthetase.


Science | 1966

Coordinate synthesis of heme and apoenzyme in the formation of tryptophan pyrrolase.

Harvey S. Marver; Donald P. Tschudy; Mark G. Perlroth; Annie Collins

Reciprocal control mechanisms between hemoprotein and 8-aminolevulinic acid synthetase take part in coordinate synthesis of the heme and apoenzyme moieties of tryptophan pyrrolase. Stimulation of heme biosynthesis increases tryptophan pyrrolase, whereas enhancement of heme binding by apotryptophan pyrrolase secondarily increases the formation of δ-aminolevulinic acid synthetase, the rate-limiting enzyme in heme formation. Tryptophan-mediated induction of δ-aminolevulinic acid synthetase suggests that heme participates in repression of that enzyme


Proceedings of the National Academy of Sciences of the United States of America | 1968

The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase.

R Tenhunen; Harvey S. Marver; R Schmid


Journal of Biological Chemistry | 1969

Microsomal Heme Oxygenase CHARACTERIZATION OF THE ENZYME

Raimo Tenhunen; Harvey S. Marver; Rudi Schmid


Journal of Biological Chemistry | 1966

δ-Aminolevulinic Acid Synthetase I. STUDIES IN LIVER HOMOGENATES

Harvey S. Marver; Donald P. Tschudy; Mark G. Perlroth; Annie Collins


Biochemistry | 1970

Reduced nicotinamide-adenine dinucleotide phosphate dependent biliverdin reductase: partial purification and characterization.

Raimo Tenhunen; Michael E. Ross; Harvey S. Marver; Rudi Schmid

Collaboration


Dive into the Harvey S. Marver's collaboration.

Top Co-Authors

Avatar

Rudi Schmid

University of California

View shared research outputs
Top Co-Authors

Avatar

Annie Collins

University of Washington

View shared research outputs
Top Co-Authors

Avatar

Donald P. Tschudy

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Perry L. Scholnick

United States Department of Veterans Affairs

View shared research outputs
Top Co-Authors

Avatar

L. James Strand

University of Texas Southwestern Medical Center

View shared research outputs
Top Co-Authors

Avatar

Allan G. Redeker

University of Southern California

View shared research outputs
Top Co-Authors

Avatar

Bertram F. Felsher

University of Southern California

View shared research outputs
Top Co-Authors

Avatar

Urs A. Meyer

University of California

View shared research outputs
Researchain Logo
Decentralizing Knowledge